 Efungumab

Efungumab (trade name Mycograb) was a drug developed by NeuTec Pharma (a subsidiary of Novartis), intended to treat invasive "Candida" infection in combination with amphotericin B.The European Medicines Agency has twice refused to grant marketing authorization for Mycograb, citing product safety and quality issues.